The Comparison of Gender Dysphoria,Body Image Satisfaction and Quality of Life Between Treatment-Naive Transgender Males With and Without Polycystic Ovary Syndrome
Restricted accessResearch articleFirst published online November, 2022
The Comparison of Gender Dysphoria,Body Image Satisfaction and Quality of Life Between Treatment-Naive Transgender Males With and Without Polycystic Ovary Syndrome
The prevalence of polycystic ovary syndrome (PCOS) among trans men has been reported as higher than among the cisgender population, which varies between 14.4% and 58%. In this cross-sectional study, we aimed to evaluate the association of oligo-anovulation and/or features of hyperandrogenism with the scores on the Utrecht Gender Dysphoria Scale (UGDS), the Body Image Scale (BIS), and the Short Form-36 Health Survey (SF-36) in treatment-naive trans men with PCOS seeking help for gender transition. The study sample consisted of trans men who were diagnosed with gender dysphoria (GD) between December 2019 and November 2020. To assess body dissatisfaction and psychological functioning, the UGDS, BIS, and SF-36 were administered to all transgender individuals as part of the routine assessment procedure. A total of 49 treatment-naive trans men were included in our study; 38.8% (n=19) of the participants were diagnosed with PCOS using the Rotterdam 2003 criteria. The scores of UGDS and BIS were significantly lower in the PCOS group compared with the non-PCOS group (p<0.001 and p=0.003, respectively). Among the eight parameters within SF-36, general health, emotional role, and vitality scores were significantly higher in the PCOS group (p=0.031, p=0.015, and p=0.006, respectively). Our study is the first study that demonstrates significantly lower GD, higher body image satisfaction and quality of life in trans men with PCOS compared with those without PCOS. Our findings are promising for larger prospective cohort studies to develop a consensus on the management of PCOS in trans men.
Get full access to this article
View all access options for this article.
References
1.
American Psychiatric Association: Diagnostic and Statistical Manual of MentalDisorders, 5th ed., text revision. DSM-V-TR ed. Washington, DC, 2013.
2.
CollinL, ReisnerSL, TangprichaV, GoodmanM. Prevalence of transgender depends on the “Case” definition: a systematic review. J Sex Med. 2016; 13:613–626.
3.
BabaT, EndoT, HonnmaH, et al.Association between polycystic ovary syndrome and female-to-male transsexuality. Hum Reprod. 2007; 22:1011–1016.
4.
VujovicS, PopovicS, Sbutega-MilosevicG, et al.Transsexualism in Serbia: a twenty-year follow-up study. J Sex Med. 2009; 6:1018–1023.
5.
ForemanM, HareL, YorkK, et al.Genetic link between gender dysphoria and sex hormone signaling. J Clin Endocrinol Metab. 2019; 104:390–396.
6.
The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004; 19:41–47.
7.
CarminaE, AzzizR. Diagnosis, phenotype, and prevalence of polycystic ovary syndrome. Fertil Steril. 2006; 86:S7.
8.
BozdagG, MumusogluS, ZenginD, et al.The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016; 31:2841–2855.
9.
KnochenhauerES, KeyTJ, Kahsar-MillerM, et al.Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998; 83:3078–3082.
DeswalR, NarwalV, DangA, PundirCS. The prevalence of polycystic ovary syndrome: a brief systematic review. J Hum Reprod Sci. 2020; 13:261–271.
12.
FutterweitW, WeissRA, FagerstromRM. Endocrine evaluation of forty female-to-male transsexuals: increased frequency of polycystic ovarian disease in female transsexualism. Arch Sex Behav. 1986; 15:69–78.
13.
Becerra-FernándezA, Pérez-LópezG, MenachoM, et al.Prevalence of hyperandrogenism and polycystic ovary syndrome in female to male transsexuals [in Turkish]. Endocrinol Nutr. 2014; 1–8.
14.
CalvarC, FernandezM, DuranY, et al. Polycystic Ovary Syndrome in Female to Male transsexual Persons. Vol. 41. BioScientifica, 2016. DOI: 10.1530/endoabs.41.EP682.
15.
BosinskiHAG, PeterM, BonatzG, et al.A higher rate of hyperandrogenic disorders in female-to-male transsexuals. Psychoneuroendocrinology. 1997; 22:361–380.
AzzizR, KintzigerK, LiR, et al.Recommendations for epidemiologic and phenotypic research in polycystic ovary syndrome: an androgen excess and PCOS society resource. Hum Reprod. 2019; 34:2254–2265.
18.
BazarganipourF, ZiaeiS, MontazeriA, et al.Body image satisfaction and self-esteem status among the patients with polycystic ovary syndrome. Int J Reprod Biomed. 2013; 11:829–836.
19.
AnnagürBB, TazegülA, AkbabaN. Body image, self-esteem and depressive symptomatology in women with polycystic ovary syndrome. Arch Neuropsychiatry. 2014; 51:129–132.
20.
GlowinskaA, DulebaAJ, Zielona-JenekM, et al.Disparate relationship of sexual satisfaction, self-esteem, anxiety, and depression with endocrine profiles of women with or without PCOS. Reprod Sci. 2020; 27:432–442.
21.
ColizziM, CostaR, TodarelloO. Transsexual patients' psychiatric comorbidity and positive effect of cross-sex hormonal treatment on mental health: results from a longitudinal study. Psychoneuroendocrinology. 2014; 39:65–73.
22.
FisherAD, CastelliniG, RistoriJ, et al.Cross-sex hormone treatment and psychobiological changes in transsexual persons: two-year follow-up data. J ClinEndocrinol Metab. 2016; 101:4260–4269.
23.
Cohen-KettenisPT, Van GoozenSHM. Sex reassignment of adolescent transsexuals: a follow-up study. J Am Acad Child Adolesc Psychiatry. 1997; 36:263–271.
24.
LindgrenTW, PaulyIB. A body image scale for evaluating transsexuals. Arch Sex Behav. 1975; 4:639–656.
25.
WareJE, SherbourneCD. The MOS 36-item short-form health survey (Sf-36): I. conceptual framework and item selection. Med Care. 1992; 30:473–483.
26.
MatthewsDR, HoskerJP, RudenskiAS, et al.Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28:412–419.
Escobar-MorrealeHF, CarminaE, DewaillyD, et al.Epidemiology, diagnosis and management of hirsutism: a consensus statement by the androgen excess and polycystic ovary syndrome society. Hum Reprod Update. 2012; 18:146–170.
29.
FerrimanD, GallweyJD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961; 21:1440–1447.
30.
KoçyiğitH, Aydemir Ö, ÖlmezN, MemisA. Reliability and validity of the Turkish version of Short Form-36 (SF-36) [in Turkish]. İlaç ve Tedavi Dergisi. 1999; 12:102–106.
31.
AlioğluF. Psychiatric Evaluation of Individuals with Gender Incongruence [Dissertation]. Kocaeli University Faculty of Medicine, Department of Psychiatry, Kocaeli University, Kocaeli, Turkey, 2020.
32.
ColemanE. Standards of care for the health of transsexual, transgender, and gender-nonconforming people: an introduction. In: Principles of Gender-Specific Medicine. (Legato MJ; ed.). Cambridge, Massachusetts: Academic Press, 2017, pp. 69–75.
33.
NguyenHB, ChavezAM, LipnerE, et al.Gender-affirming hormone use in transgender individuals: impact on behavioral health and cognition. Curr Psychiatry Rep. 2018; 20:1–9.
34.
White HughtoJM, ReisnerSL. A systematic review of the effects of hormone therapy on psychological functioning and quality of life in transgender individuals. Transgend Health. 2016; 1:21–31.
35.
BabaT, EndoT, IkedaK, et al.Distinctive features of female-to-male transsexualism and prevalence of gender identity disorder in Japan. J Sex Med. 2011; 8:1686–1693.
36.
MuellerA, GoorenLJ, Naton-schoS, et al.Hyperandrogenemia in female-to-male transsexuals. J Clin Endocrinol Metab. 2008; 93:1408–1411.
37.
SpinderT, SpijkstraJJ, Van Den TweelJG, et al.The effects of long term testosterone administration on pulsatile luteinizing hormone secretion and on ovarian histology in eugonadal female to male transsexual subjects. J Clin Endocrinol Metab. 1989; 69:151–157.
38.
MurrayAA, GosdenRG, AllisonV, SpearsN. Effect of androgens on the development of mouse follicles growing in vitro. J Reprod Fertil. 1998; 113:27–33.
39.
VendolaKA, ZhouJ, AdesanyaOO, et al.Androgens stimulate early stages of follicular growth in the primate ovary. J Clin Invest. 1998; 101:2622–2629.
40.
CaanenMR, SchoutenNE, KuijperEAM, et al.Effects of long-term exogenous testosterone administration on ovarian morphology, determined by transvaginal (3D) ultrasound in female-to-male transsexuals. Hum Reprod. 2017; 32:1457–1464.
41.
GussCE, PittsS. Remember to ask about gender: management of polycystic ovary syndrome in transgender male adolescents. J Pediatr Adolesc Gynecol. 2018; 31:182–183.
42.
GlueckCJ, GoldenbergN. Characteristics of obesity in polycystic ovary syndrome: etiology, treatment, and genetics. Metabolism. 2019; 92:108–120.
43.
NaderpoorN, ShorakaeS, JohamA, et al.Obesity and polycystic ovary syndrome. Minerva Endocrinol. 2015; 40:37–51.
44.
PolatA, YukselS, DiscigilAG, MeterisH. Family attitudes toward transgendered people in Turkey: experience from a secular Islamic country. Int J Psychiatry Med. 2005; 35:383–393.
45.
LiznevaD, SuturinaL, WalkerW, et al.Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016; 106:6–15.
46.
TehraniFR, SimbarM, TohidiM, et al.The prevalence of polycystic ovary syndrome in a community sample of Iranian population: iranian PCOS prevalence study. Reprod Biol Endocrinol. 2011; 9:39.
